Related Experiment Video
Updated: Jan 23, 2026

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
Design and biological activity of epidermal growth factor receptor-targeted peptide doxorubicin conjugate
Mingliang Fan1, Danbo Yang1, Xiaofei Liang1
1State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, No. 25/Ln2200, XieTu Rd, Shanghai 200032, China.
Abstract:
The nonspecific toxicity of anticancer drug doxorubicin (DOX) toward both tumor and normal cells can result in serious side effects, thereby limiting its clinical applications. In this wok, epidermal growth factor receptor (EGFR) antagonist peptide GE11 was introduced into DOX structure via a disulfide bond which can be cleaved by reduced glutathione (GSH). We have investigated the intracellular delivery and in vitro cytotoxicity of GE11-DOX conjugate and free DOX in high (SMMC-7721) and low (MCF-7) EGFR expressing cancer cell models. GE11-DOX accumulated at higher levels in SMMC-7721 cells than in MCF-7 cells, while the cellular uptake of free DOX was almost the same in both cells. Furthermore, pretreating with anti-EGFR monoclonal antibody reduced intracellular accumulation of GE11-DOX in SMMC-7721, indicating the involvement of EGFR pathway in the transport of conjugate. Our results suggest that GE11-DOX conjugate has the potential to be a therapeutic agent for treating EGFR overexpressing tumor.
Insights
This study introduces GE11-DOX, a targeted anticancer drug conjugate. GE11-DOX shows enhanced delivery to EGFR-overexpressing tumors, reducing side effects of doxorubicin (DOX).
Area of Science:
- Oncology
- Drug Delivery
- Bioconjugation
Background:
- Nonspecific toxicity of doxorubicin (DOX) limits its clinical use.
- Targeted drug delivery aims to reduce side effects and improve efficacy.
- Epidermal growth factor receptor (EGFR) is overexpressed in various cancers.
Purpose of the Study:
- To develop and evaluate a novel GE11-DOX conjugate for targeted cancer therapy.
- To investigate the cellular uptake and cytotoxicity of GE11-DOX in cancer cell models.
- To confirm the role of the EGFR pathway in GE11-DOX delivery.
Main Methods:
- Synthesis of GE11-DOX conjugate via a disulfide bond cleavable by reduced glutathione (GSH).
- In vitro assessment of intracellular delivery and cytotoxicity in high (SMMC-7721) and low (MCF-7) EGFR-expressing cancer cells.
- Evaluation of EGFR pathway involvement using anti-EGFR monoclonal antibody pretreatment.
Main Results:
- GE11-DOX exhibited significantly higher accumulation in EGFR-overexpressing SMMC-7721 cells compared to MCF-7 cells.
- Cellular uptake of free DOX was comparable in both cell lines, indicating targeted delivery of the conjugate.
- Inhibition of EGFR signaling reduced GE11-DOX intracellular accumulation, confirming EGFR-mediated transport.
Conclusions:
- GE11-DOX conjugate demonstrates targeted intracellular delivery via the EGFR pathway.
- The GE11-DOX conjugate shows potential as a therapeutic agent for EGFR-overexpressing tumors.
- This targeted approach may mitigate the systemic toxicity associated with conventional doxorubicin therapy.
More Related Videos
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
Related Concept Videos
Factors Influencing Microbial Growth: Osmolarity
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: pH
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Factors Affecting Activity Coefficient
The activity coefficient value for an ion is close to one when the solution has almost zero ionic strength, i.e., when the solution shows close to ideal behavior. As the ionic strength of the solution increases from 0 to 0.1 mol/L, a...